New targeted treatments in lung cancer--overview of clinical trials.

摘要: Summary Combination chemotherapy has been established as the cornerstone of systemic treatment for advanced lung cancer in last ten to fifteen years. However, improvements with new drug combinations recent years have rather small and a general outcome plateau reached one-Year survival rates about 40% two-Year less than 15%. Survival over three four is still rare event this disease, more efforts are being made develop innovative strategies mechanisms action different from conventional cytotoxic drugs. These molecular targeted agents strong move forward management disease since Gefitinib — molecule EGF-receptor tyrosine kinase inhibitor was registered 2003 by FDA number further countries third-line non-small-cell cancer. Since then, every month findings reported cellular targets on lung-cancer cells and, consequently, aiming at these developed, preclinically. Some already tested clinics within phase-I, phase-II some even randomised phase-III trials. In review we will try summarise current knowledge data clinical activity drugs give perspective future principles. The most promising family, serum-VEGF VEGF-receptor family (VEGF-1 -2, respectively). Results pivotal registration trials expected next one or two drugs, standards care may change dramatically, comparable what seen other solid tumours such metastasised breast colon